Difei Yang
Stock Analyst at Mizuho
(2.24)
# 2,755
Out of 5,115 analysts
29
Total ratings
33.33%
Success rate
13.75%
Average return
Main Sectors:
Stocks Rated by Difei Yang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AKBA Akebia Therapeutics | Downgrades: Neutral | $6 → $2 | $1.41 | +41.84% | 4 | Mar 31, 2022 | |
| NVCR NovoCure | Maintains: Neutral | $229 → $200 | $12.40 | +1,512.90% | 6 | Jul 30, 2021 | |
| CASI CASI Pharmaceuticals | Initiates: Buy | $38 | $1.02 | +3,625.49% | 1 | Apr 26, 2021 | |
| QURE uniQure | Upgrades: Buy | $52 | $22.72 | +128.87% | 4 | Apr 1, 2021 | |
| SRPT Sarepta Therapeutics | Maintains: Buy | $158 → $160 | $20.34 | +686.63% | 2 | Feb 26, 2021 | |
| XERS Xeris Biopharma Holdings | Maintains: Buy | $18 → $14 | $7.36 | +90.22% | 4 | Apr 23, 2020 | |
| NKTR Nektar Therapeutics | Upgrades: Buy | $315 → $525 | $37.33 | +1,306.38% | 4 | Feb 3, 2020 | |
| BOLD Boundless Bio | Upgrades: Buy | n/a | $1.16 | - | 2 | Aug 8, 2018 | |
| RGNX REGENXBIO | Initiates: Neutral | $28 | $11.16 | +150.90% | 1 | Feb 13, 2018 | |
| HRTX Heron Therapeutics | Initiates: Buy | $28 | $1.32 | +2,021.21% | 1 | Sep 27, 2017 |
Akebia Therapeutics
Mar 31, 2022
Downgrades: Neutral
Price Target: $6 → $2
Current: $1.41
Upside: +41.84%
NovoCure
Jul 30, 2021
Maintains: Neutral
Price Target: $229 → $200
Current: $12.40
Upside: +1,512.90%
CASI Pharmaceuticals
Apr 26, 2021
Initiates: Buy
Price Target: $38
Current: $1.02
Upside: +3,625.49%
uniQure
Apr 1, 2021
Upgrades: Buy
Price Target: $52
Current: $22.72
Upside: +128.87%
Sarepta Therapeutics
Feb 26, 2021
Maintains: Buy
Price Target: $158 → $160
Current: $20.34
Upside: +686.63%
Xeris Biopharma Holdings
Apr 23, 2020
Maintains: Buy
Price Target: $18 → $14
Current: $7.36
Upside: +90.22%
Nektar Therapeutics
Feb 3, 2020
Upgrades: Buy
Price Target: $315 → $525
Current: $37.33
Upside: +1,306.38%
Boundless Bio
Aug 8, 2018
Upgrades: Buy
Price Target: n/a
Current: $1.16
Upside: -
REGENXBIO
Feb 13, 2018
Initiates: Neutral
Price Target: $28
Current: $11.16
Upside: +150.90%
Heron Therapeutics
Sep 27, 2017
Initiates: Buy
Price Target: $28
Current: $1.32
Upside: +2,021.21%